$0.63
0.02% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
US70387R1068
Symbol
PAVM

PAVmed, Inc. Stock price

$0.63
-0.03 3.85% 1M
-0.40 38.84% 6M
+0.00 0.38% YTD
-1.20 65.58% 1Y
-13.46 95.53% 3Y
-33.11 98.13% 5Y
-167.44 99.63% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.00 0.02%
ISIN
US70387R1068
Symbol
PAVM
Sector

Key metrics

Market capitalization $10.89m
Enterprise Value $39.65m
P/E (TTM) P/E ratio 0.89
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 19.92
P/S ratio (TTM) P/S ratio 5.47
P/B ratio (TTM) P/B ratio 0.56
Revenue growth (TTM) Revenue growth -33.92%
Revenue (TTM) Revenue $1.99m
EBIT (operating result TTM) EBIT $-35.90m
Free Cash Flow (TTM) Free Cash Flow $-22.05m
Cash position $2.70m
EPS (TTM) EPS $0.71
P/E forward 3.50
P/S forward 74.33
EV/Sales forward 270.65
Short interest 1.66%
Show more

Is PAVmed, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

PAVmed, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a PAVmed, Inc. forecast:

2x Buy
100%

Analyst Opinions

2 Analysts have issued a PAVmed, Inc. forecast:

Buy
100%

Financial data from PAVmed, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
1.99 1.99
34% 34%
100%
- Direct Costs 3.79 3.79
61% 61%
190%
-1.79 -1.79
73% 73%
-90%
- Selling and Administrative Expenses 29 29
30% 30%
1,441%
- Research and Development Expense 4.78 4.78
61% 61%
240%
-35 -35
41% 41%
-1,771%
- Depreciation and Amortization 0.66 0.66
77% 77%
33%
EBIT (Operating Income) EBIT -36 -36
43% 43%
-1,804%
Net Profit 74 74
220% 220%
3,717%

In millions USD.

Don't miss a Thing! We will send you all news about PAVmed, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

PAVmed, Inc. Stock News

Neutral
Seeking Alpha
5 days ago
PAVmed Inc. (NASDAQ:PAVM ) Q1 2025 Earnings Conference Call May 15, 2025 8:30 AM ET Company Participants Matt Riley - Senior Director of Investor Relations Lishan Aklog - Chairman and Chief Executive Officer Dennis McGrath - Chief Financial Officer Conference Call Participants Jeremy Pearlman - Maxim Group Edward Woo - Ascendiant Capital Operator Good morning, and welcome to the PAVmed's First ...
Neutral
PRNewsWire
6 days ago
Lucid secured capital to extend runway well past key upcoming reimbursement milestones; ended 1Q25 with over $40 million in proforma cash Veris Health completed 1Q25 financing, resumed development of implantable physiological monitor, and will soon launch first commercial partnership with major cancer center PAVmed seeking to leverage infrastructure and expand into biopharma sector; actively ev...
Neutral
PRNewsWire
7 days ago
Processed 3,034 EsoGuard® tests and recognized revenue of $0.8 million in 1Q25 Secured capital to extend runway well past key upcoming reimbursement milestones; ended 1Q25 with over $40 million in proforma cash Conference call and webcast to be held today, May 14 th, at 8:30 AM EDT NEW YORK , May 14, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commerc...
More PAVmed, Inc. News

Company Profile

PAVmed, Inc. is a medical device company, which develops and commercializes a pipeline of medical products. Its product portfolio includes DisappEAR, PORTIO, Caldus, Carpx, NextCath, and NextFlo. The firm conducts its operations in four divisions: GI Health, Minimally Invasive Interventions, Infusion Therapy and Emerging Innovations. The GI Health division consists of Edouard Esophageal DNA Test, EsoCheck Esophageal Cell Collection Device, and EsoCure Esophageal Ablation Device with Caldus Technology. The Minimally Invasive Interventions division consists of CarpX, which is a patented, single-use disposable, minimally invasive device designed to treat carpal tunnel syndrome. The Infusion Therapy division consists of PortIO, which is a novel, patented, implantable, intraosseous vascular medical device; and NextFlo, which is designed to deliver gravity-driven infusions independent of the height of the IV bag. The Emerging Innovations division refers to a diversified and expanding portfolio of innovative products designed to address unmet clinical needs across a broad range of clinical conditions. The company was founded on June 26, 2014 and is headquartered in New York, NY.

Head office United States
CEO Lishan Aklog
Employees 39
Founded 2014
Website www.pavmed.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today